Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00429234 · ClinicalTrials.gov registry record · Phase 1

Gemcitabine and Dasatinib in Advanced Solid Tumors

A Phase 1 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
54
Enrollment target

NCT00429234: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.

NCT00429234 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 54 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00429234, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
54 participants
Enrollment target

Study Summary

The goal of this clinical research study is to find the highest tolerable dose of dasatinib in combination with gemcitabine that can be given to patients with advanced solid tumors. The safety of this combination of study drugs will also be studied. Researchers also want to study the pharmacodynamics (PDs) of this study drug combination. PD testing is used to learn what effect the drugs have on your tumors.

Interventions

  • DRUG Gemcitabine
  • DRUG Dasatinib

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2007-01
Est. Completion 2013-02
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00429234 record still lists

NCT00429234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower).

The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.

NCT00429234 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00429234 about?

NCT00429234 is a clinical study titled "Gemcitabine and Dasatinib in Advanced Solid Tumors". The goal of this clinical research study is to find the highest tolerable dose of dasatinib in combination with gemcitabine that can be given to patients with advanced solid tumors. The safety of this combination of study drugs will also be studied. Researchers also want to study the pharmacodynami...

What is the current status of trial NCT00429234?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2007-01. Estimated completion is 2013-02.

What interventions are being tested in trial NCT00429234?

The interventions under investigation include: Gemcitabine (DRUG), Dasatinib (DRUG).

Who is sponsoring clinical trial NCT00429234?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00429234's enrollment target sits among peer trials

54 931st of 2000 higher than 1,053 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00429234, the US trial registry maintained by the National Library of Medicine. NCT00429234 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.